Key Record Dates
| ClinicalTrials.gov Identifier: | NCT05646862 |
|---|---|
| Brief Title: | A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy (INAVO121) |
| First Submitted : | December 2, 2022 |
| First Submitted that Met QC Criteria : | December 2, 2022 |
| First Posted : | December 12, 2022 |
| Last Update Submitted that Met QC Criteria : | April 24, 2024 |
| Last Update Posted : | April 25, 2024 |